Stock Trading Canary
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 81Established evidence | 100.0% (81/81) | 61.7% (50/81) | +1.0% | +1.3% | -5.8% |
| 20D | 77Established evidence | 100.0% (77/77) | 58.4% (45/77) | +3.2% | +2.9% | -9.8% |
| 60D | 64Established evidence | 100.0% (64/64) | 71.9% (46/64) | +4.2% | +6.0% | -12.3% |
| 120D | 50Established evidence | 100.0% (50/50) | 48.0% (24/50) | -0.6% | -0.1% | -12.8% |
COMPANY RESEARCH
EUROFINS SCIENTIFIC SE
ERF.PA · Luxembourg · Healthcare · Diagnostics & Research
Insider Signal
Snapshot: 05 Nov 2026 · 180-day research window
- Insider Signal
- 47.8 / 100 Research score, not a buy recommendation
- Reported buyers
- 1 180-day scoring window
- Net purchases
- 4.52m EUR 180 days · purchases less sales
- Latest disclosure
- 2026-10-22 Publication date
What stands out
- Analytical Bioventures S.C.A accounts for 100% of comparable reported purchase value; buyer breadth and value are different measures.
Price vs insider buying
ERF.PA · EUR● Purchase × Sale ◇ Public disclosure ▥ 15-day cluster ·
Circles and crosses mark trade dates; diamonds below the axis mark later public disclosures. The trade became public on its disclosure date. Prices are nearest-session closes, not insider execution prices. Marker sizes are not compared when values or currencies differ.
BULL VS BEAR
Two readings of this buying
The same filings, read two ways. Each line is a fact stored for this company with the number behind it, and appears only when that number crosses a fixed threshold. Neither side is a forecast and no winner is declared.
Since 2026-11-03: no longer on the bull side: bought in the last two weeks; new on the bear side: one buyer only. All bull and bear lists, and what followed each line in the past →
Where the evidence comes from
Independent evidence does not object: the purchases themselves carry bull lines (senior executive buying, buyer's past purchases beat the benchmark); share price and trading, short sellers, company results were checked and none crosses a bear threshold. No data is held for: company actions.
- The insider purchases themselvesBullsenior executive buying, buyer's past purchases beat the benchmark Bearone buyer only, small purchases3 checked, under the threshold · 2 missing
- Share price and trading3 checked, under the threshold
- Short sellers1 checked, under the threshold
- Company results1 checked, under the threshold · 1 missing
- Company actionsno data held
Bull case · the buying is informative
- The buyers include the CEO or chair, who sees more of the business than most filers. This site's score gives little or no credit for that: in its backtests purchases by senior executives did no better than other insiders' purchases.Record: after 8,812 earlier disclosures like this, the median 60-session excess return was −3.1%, within 1 percentage point of all comparable disclosures (−3.4%).
- The 64 earlier purchases by Analytical Bioventures S.C.A beat STOXX Europe 600 (regional proxy) by a median 4.2% over the following 60 trading days.
Bear case · discount it
- Only one insider bought. A single purchase can reflect that person's own finances rather than a view on the company.Record: after 4,900 earlier disclosures like this, the median 60-session excess return was −3.0%, within 1 percentage point of all comparable disclosures (−3.4%).
- Insider purchases in the last 20 sessions equal 0.07% of the stock's traded value over those sessions: too small to register in the market.
Evidence still missing
- Only one reading of profitability is held (profit margin 7.2%). Whether earnings and cash flow are rising or falling needs the last two reports side by side.
- European notifications have no field saying whether a purchase was pre-arranged; there is no counterpart to the US 10b5-1 box. None of the 82 purchase lines mentions a plan, but a bare “Acquisition of shares Price(s) Volume(s)” does not rule one out.
- The filings give the size of each trade, not what the buyer already held. Whether a purchase added 1% to a personal stake or doubled it is not known.
Checked and under the threshold: 8, 1 close to it
- EitherThe latest purchase is 15 days old. Bull up to 14 days, bear from 90. close to the threshold
- Bear0 of 1 buyer filed as a person closely associated with a manager. Counted for the bear side from half.
- BearInsiders sold €621k in the same 180 days, 12% of the amount bought. Counted for the bear side from 25%.
- BearThe share price changed +49% over six months (three months +26%, one month +16%). Counted for the bear side from a fall of 20%.
- BearOver three months the share price changed +26% and the median of 387 Healthcare companies changed −4.5%: ahead by 31 points. Counted for the bear side from 20 points behind.
- BearPublished net short positions add up to 0.50% of the share capital across 1 named holder. Counted for the bear side from 2%. Unchanged since 2026-10-22.
- BearProfit margin on the latest captured figures is 7.2%. Counted for the bear side when negative.
- BearAbout €24.8M of the stock changes hands on an average day. Counted for the bear side below €500k.
Both columns arrange stored facts only. They do not change the insider score or the ranking and are not investment advice.
Who is trading?
Named filings in 180 days. Purchase values are summed only when complete and in one currency.
| Insider | Transaction activity | Purchase value | Latest trade | Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Analytical Bioventures S.C.ACEO / chair | 82 buy · 0 sell | 5.15m EUR | 2026-10-21 | View transactions · 82
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Laurent LebrasCFO | 0 buy · 3 sell | No purchases | 2026-09-21 | View transactions · 4
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| VIGNEAU FrançoisCEO / chair | 0 buy · 6 sell | No purchases | 2026-09-21 | View transactions · 11
|
INSIDER SIGNAL
Score breakdown：47.8 / 100
1 insiders · 82 purchase events · €4.52m net purchases
Europe #725 · Luxembourg #4
WHY THIS SIGNAL?
Score anatomy
Each bar is that part's points in the score; the five parts add up to the score.
Number of buyers+10.5 / 35
How many different insiders bought within 15 days
Amount bought+24.9 / 25
The value bought, net of any insider sales
Buyers' roles+0.0 / 20
Lower in the company scores higher: in the backtest, purchases by the most senior insiders did worse
How recent+3.5 / 10
How long ago the latest purchase took place
Buying against selling+8.9 / 10
Lower when insiders also sold
What is holding the score back?
- ⚠ Few buyers · fewer than 4 different insiders
- ⚠ Buyers' roles add little · most senior buyer: CEO / chair; the most senior score lowest
- ⚠ The latest purchase was some time ago
Buyers' roles follow the European ranking's order of roles: the most senior insiders score lowest.
Buying concentration
100%
Largest buyer：Analytical Bioventures S.C.A · 5.15m EUR
Purchases counted, before sales：5.15m EUR
The amount at the top of the page is purchases minus sales; this one counts purchases only, in the filing currency, so the two can differ. The score counts how many people bought; this shows separately who bought the most.
This is a ranking under the current European screening rules—not a probability of gain, return forecast, or buy recommendation.
Key purchase quotes (filing currency)
| Filer | Price per unit | Trade date |
|---|---|---|
| Analytical Bioventures S.C.A | 79.2918 EUR | Oct 21, 2026 |
| Analytical Bioventures S.C.A | 78.8091 EUR | Oct 20, 2026 |
| Analytical Bioventures S.C.A | 64.8451 EUR | Jun 23, 2026 |
Model details
Cluster breakdown (does not change the score)
- 15-day buyer breadth (count)
- 1 distinct reported filers
- Peak time window
- 2026-06-17 to 2026-07-02
- Current breadth input
- 0.300 (capped at 4+ buyers)
- Buyer independence
- Not yet measured; related-party fields are not cross-market comparable
What the filings show
- 🟢 Latest purchase counted
Analytical Bioventures S.C.A · 9k EUR · Price 79.2918 EUR · Oct 21, 2026 - 🟢 Purchase counted
Analytical Bioventures S.C.A · 39k EUR · Price 78.8091 EUR · Oct 20, 2026 - 🟢 Large purchase counted
Analytical Bioventures S.C.A · 130k EUR · Price 64.8451 EUR · Jun 23, 2026 - 🟡 79 more purchase line(s) counted, from 79 filing(s)
- 🔴 26 other line(s) are not counted, as they are not purchases the insider chose to make; 0 have a price of zero
Filing and data quality
These checks are auditable context; they do not change the rank or score.
- Identity match
- PASS · isin
- Ticker / ISIN
- Present
- Filing source links
- 0 / 125
- Median disclosure lag
- 3 days
- Latest disclosure age
- 14 days at snapshot
- Corrections / revisions
- 0
- Score-factor detail
- Saved
Insider timeline
One insider bought, 82 times, the latest (21 Oct). The share closed at 80.90 that day and at 88.02 most recently (+8.8%).
Tap an item for what it means.
●A purchase: the bigger the dot, the more was bought
Each dot is one insider's purchases on one day. The dot's area follows the amount: the largest purchase here gets the largest dot. Hold the pointer over a dot to see the date and the amount.
×A sale
A cross is one insider's sales on one day. People sell to pay tax, to cash in share awards or to hold less of one company, so a sale says less than a purchase does. When someone bought and sold on the same day, the cross sits beside the dot. The totals are under “Purchases against sales” below.
Blue line: this share's price, +50.4% over these six months
The closing price of each day, from 58.52 on 2026-05-11 to 88.02 on 2026-11-04. The line has no scale; read it for high and low: a dot on a low stretch was bought cheaply, a dot on a high stretch was not.
Dashed line: the typical stock on the same exchange, −6.5%
Taken from the 137 other stocks on the same exchange that this site holds prices for. Each is measured from the first day of the window, and every day the middle one is drawn. It starts where the blue line starts, so the gap between the two is the difference: this share +50.4%, the typical one −6.5%, 56.9 points ahead. It is not an index and not a comparison within one industry.
▂Grey bars: companies across Europe disclosing purchases each week
A taller bar is a week in which more companies disclosed insider purchases.
This company: insiders buying per month, last 12 months
Dec
Jan
Feb
1Mar
1Apr
1May
1Jun
1Jul
1Aug
1Sep
1Oct
Nov
Darker bars are inside the 180-day window above.
Who traded
| Insider | Role | Purchases | Sales | Bought | First purchase | Share price since | Earlier purchases |
|---|---|---|---|---|---|---|---|
| VIGNEAU François | CEO / chair | — | 6 | — | — | — | fewer than 5 completed |
| Analytical Bioventures S.C.A | CEO / chair | 82 | — | 5.1M EUR | 2026-06-17 | +40.7% | 64 completed, median +4.2% against peers after 60 sessions |
| Laurent Lebras | CFO | — | 3 | — | — | — | fewer than 5 completed |
Purchases against sales
Purchases89%5.1M EUR · 82 line(s) · 1 insider(s)
Sales11%621.4k EUR · 9 line(s) · 2 insider(s)
Shares of the reported value of insider transactions in the 180-day window. Sales include disposals for tax, at option exercise or under a pre-set plan, which say little about an insider's view. The split describes what was disclosed; it is not a signal.
Insiders' buying price vs the latest close
Insiders paid 64.95 EUR a share on average (93 purchase lines, 2 buyers, 2026-03-18 – 2026-10-21). The close on 2026-11-04 was 35.5% above that price.
The latest purchase (2026-10-21) was at 79.29 EUR; the close was 11.0% above that price.
Prices paid are weighted by shares and taken from the filings; dividends are not counted. Not scored.
Buying size vs market trading
0.07% · of estimated traded value in the same period
2026-10-08 – 2026-11-04 · 20 recorded trading sessions
- Disclosed qualifying purchases
- 359,588 EUR
- Estimated market traded value
- 496,210,491 EUR
Market-data coverage: 516 verified sessions · Latest session: 2026-11-04 · Ratio status: Available
Recent and largest purchase events / preceding 60-session ADTV
- Oct 21 · Analytical Bioventures S.C.A · S.E., CEO Dr. Gilles Martin9,039 EUR · 0.04%21,319,591 EUR ADTV
- Oct 20 · Analytical Bioventures S.C.A · S.E., CEO Dr. Gilles Martin39,405 EUR · 0.18%21,331,615 EUR ADTV
- Oct 19 · Analytical Bioventures S.C.A · S.E., CEO Dr. Gilles Martin39,304 EUR · 0.18%21,317,786 EUR ADTV
- Oct 16 · Analytical Bioventures S.C.A · S.E., CEO Dr. Gilles Martin39,330 EUR · 0.19%21,232,760 EUR ADTV
- Oct 15 · Analytical Bioventures S.C.A · S.E., CEO Dr. Gilles Martin39,318 EUR · 0.18%21,328,363 EUR ADTV
- Oct 14 · Analytical Bioventures S.C.A · S.E., CEO Dr. Gilles Martin38,881 EUR · 0.18%21,057,571 EUR ADTV
- Oct 13 · Analytical Bioventures S.C.A · S.E., CEO Dr. Gilles Martin39,068 EUR · 0.19%21,056,347 EUR ADTV
- Sep 08 · Analytical Bioventures S.C.A · S.E., CEO Dr. Gilles Martin108,662 EUR · 0.66%16,566,741 EUR ADTV
Traded value is estimated as close × shares traded, in major currency units. Includes disclosed qualifying purchases; disclosures may lag. Contractual or planned acquisitions are not necessarily discretionary. Ratios describe relative trading size, not market participation or score contributions.
Sector context
- Buying breadth
- 4.6% (36 / 785 issuers)
- Sector rank
- #12 / 12
- 7D breadth change
- +0.4 pp · vs 2026-10-29 (7d)
- 30D breadth change
- History building
This is sector-level research context. It does not affect the Insider Signal or ranking.
Insider profile outcomes
Historical performance following insider filings. The company role is translated below each name while preserving the original title.
- Excess return = stock return − STOXX Europe 600 (regional proxy) return over the same period.
- Hit rate = completed events with positive excess return ÷ total completed events.
- Price coverage = valid point-in-time prices ÷ events mature enough for that period.
- Returns start on the first shared trading session on or after publication.
- Small-sample rule: n<5 is shown for transparency and is not scored.
Events are disclosure-level observations; related disclosures published on the same date may share a return path and may not be statistically independent. This research enrichment does not affect the insider score or ranking.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 2Small sample | 100.0% (2/2) | 0.0% (0/2) | -1.6% | -1.6% | -2.2% |
| 20D | 2Small sample | 100.0% (2/2) | 0.0% (0/2) | -1.8% | -1.8% | -3.2% |
| 60D | 2Small sample | 100.0% (2/2) | 0.0% (0/2) | -10.2% | -10.2% | -10.9% |
| 120D | 2Small sample | 100.0% (2/2) | 0.0% (0/2) | -2.5% | -2.5% | -2.5% |
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 2Small sample | 100.0% (2/2) | 50.0% (1/2) | +0.7% | +0.7% | -3.6% |
| 20D | 2Small sample | 100.0% (2/2) | 50.0% (1/2) | +4.9% | +4.9% | -1.1% |
| 60D | 2Small sample | 100.0% (2/2) | 100.0% (2/2) | +7.8% | +7.8% | +3.7% |
| 120D | 2Small sample | 100.0% (2/2) | 100.0% (2/2) | +33.6% | +33.6% | +25.0% |
Market context
PRICE PERFORMANCE
VOLATILITY & LIQUIDITY
- Volatility
- 27.6%
- Beta
- 0.81
- Avg daily volume
- €27.1M
- 20-session drawdown
- -1.1%
- 60-session drawdown
- -5.6%
- Latest volume / prior median
- 1.3×
VALUATION
- Market cap
- €14.8B
- Market cap (EUR ref.)
- €14.8B
- P/E
- 29.7×
FUNDAMENTALS
- Revenue
- $7.0B
- Net income
- $405.5M
- Operating profit
- $680.5M
- Equity
- $5.4B
- Cash
- $613.9M
- Debt
- —
- Operating cash flow
- $1.3B
- Free cash flow
- —
- Profit margin
- 7.2%
- ROE
- 11.3%
- Industry
- Diagnostics & Research
Prices to 04 Nov 2026: price cache (yfinance). From OpenBB/yfinance, captured 29 Oct 2026: Market cap, P/E, Profit margin, ROE, Beta, Industry. From the company's annual report ↗, fiscal year ended 31 Dec 2024: Revenue, Net income, Equity, Operating profit, Cash, Operating cash flow. ECB EUR reference rate dated 2026-11-05; it is not a trade-date conversion. It does not affect the insider score or rank.
Dividends
- Dividend yield
- 0.8%at €87.72
- Last 12 months
- €0.72per share
- Payout ratio
- 25%of 12-month earnings
- Latest ex-dividend
- 2026-04-28€0.72
- Frequency
- Annual
- Dividend growth
- -15.7%a year, 2022–2025
- By year
By year
| Year | Payments | Cash per share |
|---|---|---|
| 2026 (so far) | 1 | €0.72 |
| 2025 | 1 | €0.60 |
| 2024 | 1 | €0.50 |
| 2023 | 1 | €1.00 |
| 2022 | 1 | €1.00 |
Yahoo Finance: cash dividends by ex-dividend date, the latest close, the payout ratio (dividends ÷ 12-month earnings per share) and announced dates; special dividends included, stock dividends and splits not. Not part of any score.
Disclosed net short positions
The register for this issuer's home market (LU) is not captured; the figures below cover only positions notified to the AMF.
- Sum of published positions
- 0.50%
- Named holders
- 1
- Latest position date
- 21 Sep 2026
| Holder | Net short, % of issued share capital | Position date | Notice age |
|---|---|---|---|
| AQR CAPITAL MANAGEMENT, LLC | 0.50% | 21 Sep 2026 | Recent (90 days or less) |
Only positions of 0.5% or more are published, so the sum is a lower bound, not total short interest. Each row is the holder's latest notice, the notices have different dates, and the register still lists them all. A holder must notify every change of 0.1 points and a fall below 0.5%, so a row with an old date should mean the position has not moved since, but it can also be a notice that was never sent; whether it is still open is not confirmed. The age marks (recent, older, not updated for over a year) are this site's display rule, not a regulatory one. Source: AMF · read 06 Nov 2026
Short-position disclosures are external context; they do not affect the insider score, ranking, or filing eligibility.
Latest news
No news has been captured for this company.
Regulatory filings
The filing records held for this company carry no link to the original notice.
Filing evidence
These are underlying national-feed records from the 365-day window ending on the saved ranking snapshot. The score uses only the latest 180 days; older qualifying equity purchases remain visible for audit but do not enter the current score. The original filer, role, transaction classification, instrument, price, volume, value and source fields are retained. The first three rows are shown; remaining records can be unfolded for audit. Other transaction types are retained but excluded from the score.
Excluded transactions & classification
93 qualifying purchase disclosure(s) · 93 transaction line(s)
Trade Oct 21, 2026Acquisition of shares Price(s) Volume(s)
Analytical Bioventures S.C.A · S.E., CEO Dr. Gilles Martin
Published Oct 22, 2026 · Shares · 114.0 shares × 79.2918 EUR · —
—Trade Oct 20, 2026Acquisition of shares Price(s) Volume(s)
Analytical Bioventures S.C.A · S.E., CEO Dr. Gilles Martin
Published Oct 22, 2026 · Shares · 500.0 shares × 78.8091 EUR · —
—Trade Oct 19, 2026Acquisition of shares Price(s) Volume(s)
Analytical Bioventures S.C.A · S.E., CEO Dr. Gilles Martin
Published Oct 22, 2026 · Shares · 500.0 shares × 78.6079 EUR · —
—Unfold all 90 remaining filing row(s)
| Transaction date | Published | Filer | Role | Transaction | Instrument | Price (local currency) | Quote currency | Volume | Source |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | 2026-10-19 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 78.6605 EUR | EUR | 500.0 | — |
| 2026-10-15 | 2026-10-19 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 78.6364 EUR | EUR | 500.0 | — |
| 2026-10-14 | 2026-10-19 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 77.7614 EUR | EUR | 500.0 | — |
| 2026-10-13 | 2026-10-14 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 78.1351 EUR | EUR | 500.0 | — |
| 2026-10-12 | 2026-10-14 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 77.727 EUR | EUR | 500.0 | — |
| 2026-10-09 | 2026-10-14 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 76.5708 EUR | EUR | 500.0 | — |
| 2026-10-08 | 2026-10-09 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 76.1897 EUR | EUR | 500.0 | — |
| 2026-10-07 | 2026-10-09 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 76.1579 EUR | EUR | 500.0 | — |
| 2026-10-06 | 2026-10-09 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 77.618 EUR | EUR | 500.0 | — |
| 2026-10-05 | 2026-10-07 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 75.7987 EUR | EUR | 500.0 | — |
| 2026-10-02 | 2026-10-07 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 74.6533 EUR | EUR | 1000.0 | — |
| 2026-10-01 | 2026-10-02 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 74.7402 EUR | EUR | 1000.0 | — |
| 2026-09-30 | 2026-10-02 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 75.4839 EUR | EUR | 610.0 | — |
| 2026-09-29 | 2026-10-02 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 77.0708 EUR | EUR | 500.0 | — |
| 2026-09-28 | 2026-09-29 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 78.2729 EUR | EUR | 500.0 | — |
| 2026-09-25 | 2026-09-29 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 77.4156 EUR | EUR | 500.0 | — |
| 2026-09-24 | 2026-09-29 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 77.0889 EUR | EUR | 500.0 | — |
| 2026-09-23 | 2026-09-24 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 77.8182 EUR | EUR | 500.0 | — |
| 2026-09-22 | 2026-09-24 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 78.4553 EUR | EUR | 500.0 | — |
| 2026-09-21 | 2026-09-24 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 77.5038 EUR | EUR | 500.0 | — |
| 2026-09-18 | 2026-09-21 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 77.3197 EUR | EUR | 500.0 | — |
| 2026-09-17 | 2026-09-21 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 76.1856 EUR | EUR | 500.0 | — |
| 2026-09-16 | 2026-09-21 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 73.85 EUR | EUR | 1000.0 | — |
| 2026-09-15 | 2026-09-16 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 72.7333 EUR | EUR | 1000.0 | — |
| 2026-09-14 | 2026-09-16 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 72.3118 EUR | EUR | 1000.0 | — |
| 2026-09-11 | 2026-09-16 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 71.232 EUR | EUR | 1000.0 | — |
| 2026-09-10 | 2026-09-11 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 71.1166 EUR | EUR | 1000.0 | — |
| 2026-09-09 | 2026-09-11 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 71.3257 EUR | EUR | 1000.0 | — |
| 2026-09-08 | 2026-09-11 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 70.6518 EUR | EUR | 1538.0 | — |
| 2026-09-07 | 2026-09-08 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 71.6177 EUR | EUR | 1000.0 | — |
| 2026-09-04 | 2026-09-08 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 73.1502 EUR | EUR | 1000.0 | — |
| 2026-09-03 | 2026-09-08 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 73.6901 EUR | EUR | 1000.0 | — |
| 2026-09-02 | 2026-09-03 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 72.2629 EUR | EUR | 1000.0 | — |
| 2026-09-01 | 2026-09-03 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 72.5323 EUR | EUR | 1000.0 | — |
| 2026-08-31 | 2026-09-04 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 71.8782 EUR | EUR | 1000.0 | — |
| 2026-08-19 | 2026-08-24 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 69.5978 EUR | EUR | 741.0 | — |
| 2026-08-18 | 2026-08-19 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 69.6947 EUR | EUR | 1000.0 | — |
| 2026-08-17 | 2026-08-19 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 69.6077 EUR | EUR | 1000.0 | — |
| 2026-08-14 | 2026-08-19 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 69.9838 EUR | EUR | 224.0 | — |
| 2026-08-12 | 2026-08-14 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 69.5378 EUR | EUR | 1000.0 | — |
| 2026-08-11 | 2026-08-14 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 69.7922 EUR | EUR | 1000.0 | — |
| 2026-08-10 | 2026-08-12 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 69.7657 EUR | EUR | 1000.0 | — |
| 2026-08-07 | 2026-08-12 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 69.9148 EUR | EUR | 1000.0 | — |
| 2026-08-06 | 2026-08-07 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 69.9473 EUR | EUR | 901.0 | — |
| 2026-08-05 | 2026-08-07 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 69.3747 EUR | EUR | 1000.0 | — |
| 2026-08-04 | 2026-08-07 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 68.638 EUR | EUR | 1000.0 | — |
| 2026-08-03 | 2026-08-04 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 68.4027 EUR | EUR | 1000.0 | — |
| 2026-07-31 | 2026-08-04 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 68.665 EUR | EUR | 1000.0 | — |
| 2026-07-30 | 2026-08-04 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 68.7187 EUR | EUR | 1000.0 | — |
| 2026-07-29 | 2026-08-03 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 67.9534 EUR | EUR | 1000.0 | — |
| 2026-07-28 | 2026-07-29 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 67.4979 EUR | EUR | 1000.0 | — |
| 2026-07-27 | 2026-07-29 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 67.0658 EUR | EUR | 1000.0 | — |
| 2026-07-24 | 2026-07-29 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 66.1272 EUR | EUR | 1062.0 | — |
| 2026-07-23 | 2026-07-24 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 66.8873 EUR | EUR | 1000.0 | — |
| 2026-07-22 | 2026-07-24 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 69.6819 EUR | EUR | 765.0 | — |
| 2026-07-21 | 2026-07-24 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 69.6184 EUR | EUR | 1000.0 | — |
| 2026-07-17 | 2026-07-21 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 70.0 EUR | EUR | 9.0 | — |
| 2026-07-16 | 2026-07-21 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 68.9817 EUR | EUR | 1000.0 | — |
| 2026-07-15 | 2026-07-16 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 69.237 EUR | EUR | 1000.0 | — |
| 2026-07-14 | 2026-07-16 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 68.92 EUR | EUR | 1000.0 | — |
| 2026-07-13 | 2026-07-16 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 69.1899 EUR | EUR | 1000.0 | — |
| 2026-07-10 | 2026-07-13 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 69.5944 EUR | EUR | 1000.0 | — |
| 2026-07-09 | 2026-07-13 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 67.5759 EUR | EUR | 1000.0 | — |
| 2026-07-08 | 2026-07-13 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 67.2082 EUR | EUR | 1000.0 | — |
| 2026-07-07 | 2026-07-08 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 69.5747 EUR | EUR | 1000.0 | — |
| 2026-07-06 | 2026-07-08 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 69.58 EUR | EUR | 1000.0 | — |
| 2026-07-03 | 2026-07-08 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 69.204 EUR | EUR | 1000.0 | — |
| 2026-07-02 | 2026-07-03 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 68.8568 EUR | EUR | 1000.0 | — |
| 2026-07-01 | 2026-07-03 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 68.2377 EUR | EUR | 1000.0 | — |
| 2026-06-30 | 2026-07-03 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 68.4625 EUR | EUR | 1000.0 | — |
| 2026-06-29 | 2026-06-30 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 68.4011 EUR | EUR | 1000.0 | — |
| 2026-06-26 | 2026-06-30 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 68.4577 EUR | EUR | 1000.0 | — |
| 2026-06-25 | 2026-06-30 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 67.7737 EUR | EUR | 1000.0 | — |
| 2026-06-24 | 2026-06-25 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 66.5766 EUR | EUR | 1000.0 | — |
| 2026-06-23 | 2026-06-25 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 64.8451 EUR | EUR | 2000.0 | — |
| 2026-06-22 | 2026-06-25 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 62.7214 EUR | EUR | 2000.0 | — |
| 2026-06-19 | 2026-06-22 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 62.746 EUR | EUR | 2000.0 | — |
| 2026-06-18 | 2026-06-22 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 62.1825 EUR | EUR | 2000.0 | — |
| 2026-06-17 | 2026-06-22 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 62.27 EUR | EUR | 2000.0 | — |
| 2026-05-07 | 2026-05-11 | Sean Murray | EVP, Life Testing North America | Acquisition of shares Price(s) Volume(s) | Shares | 61.54 EUR | EUR | 61538.0 | — |
| 2026-04-23 | 2026-04-27 | Sean Murray | EVP, Life Testing North America | Acquisition of shares Price(s) Volume(s) | Shares | 62.59 EUR | EUR | 43810.0 | — |
| 2026-03-30 | 2026-03-31 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 61.8082 EUR | EUR | 1867.0 | — |
| 2026-03-27 | 2026-03-31 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 61.779 EUR | EUR | 2000.0 | — |
| 2026-03-26 | 2026-03-31 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 62.0751 EUR | EUR | 2000.0 | — |
| 2026-03-25 | 2026-03-26 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 61.8359 EUR | EUR | 2000.0 | — |
| 2026-03-24 | 2026-03-26 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 61.2166 EUR | EUR | 2000.0 | — |
| 2026-03-23 | 2026-03-26 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 59.9847 EUR | EUR | 2500.0 | — |
| 2026-03-20 | 2026-03-23 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 61.7766 EUR | EUR | 2000.0 | — |
| 2026-03-19 | 2026-03-23 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 61.6516 EUR | EUR | 2000.0 | — |
| 2026-03-18 | 2026-03-23 | Analytical Bioventures S.C.A | S.E., CEO Dr. Gilles Martin | Acquisition of shares Price(s) Volume(s) | Shares | 62.7889 EUR | EUR | 2000.0 | — |
Showing 93 of 93 matching raw-feed row(s) from the current 365-day research window. Prices and reported values remain in the filing currency and its major unit (for example, UK pence are parsed as GBP). The screen-level € aggregate is separately FX-normalised for research ranking, not a trade-date conversion.
Other disclosed transactions · excluded from score
View 32 other transaction(s)
Trade Oct 5, 2026—
— · —
Published Oct 5, 2026 · — · — shares × — · —
—Trade Sep 29, 2026—
— · —
Published Sep 29, 2026 · — · — shares × — · —
—Trade Sep 23, 2026—
— · —
Published Sep 23, 2026 · — · — shares × — · —
—Unfold all 29 remaining filing row(s)
| Transaction date | Published | Filer | Role | Transaction | Instrument | Price (local currency) | Quote currency | Volume | Source |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-21 | 2026-09-24 | Laurent Lebras | CFO | Sale of shares is linked to the Eurofins stock option / free share / stock option program Price(s) Volume(s) | Shares | 78.0 EUR | EUR | 1000.0 | — |
| 2026-09-21 | 2026-09-24 | VIGNEAU François | Senior Vice President | Sale of shares is linked to the Eurofins stock option / free share / stock option program Price(s) Volume(s) | Shares | 77.62 EUR | EUR | 500.0 | — |
| 2026-09-21 | 2026-09-21 | — | — | — | — | — | EUR | — | — |
| 2026-09-17 | 2026-09-21 | Laurent Lebras | CFO | Sale of shares is linked to the Eurofins stock option / free share / stock option program Price(s) Volume(s) | Shares | 75.0 EUR | EUR | 3000.0 | — |
| 2026-09-11 | 2026-09-15 | VIGNEAU François | Senior Vice President | Sale of shares is linked to the Eurofins stock option / free share / stock option program Price(s) Volume(s) | Shares | 71.34 EUR | EUR | 500.0 | — |
| 2026-09-11 | 2026-09-11 | — | — | — | — | — | EUR | — | — |
| 2026-09-02 | 2026-09-07 | VIGNEAU François | Senior Vice President | Sale of shares is linked to the Eurofins stock option / free share / stock option program Price(s) Volume(s) | Shares | 71.7142 EUR | EUR | 500.0 | — |
| 2026-09-02 | 2026-09-04 | Laurent Lebras | CFO | Sale of shares is linked to the Eurofins stock option / free share / stock option program Price(s) Volume(s) | Shares | 73.0 EUR | EUR | 1000.0 | — |
| 2026-08-31 | 2026-08-31 | — | — | — | — | — | EUR | — | — |
| 2026-08-28 | 2026-09-01 | VIGNEAU François | Senior Vice President | Sale of shares is linked to the Eurofins stock option / free share / stock option program Price(s) Volume(s) | Shares | 72.805 EUR | EUR | 500.0 | — |
| 2026-08-27 | 2026-09-01 | Laurent Lebras | CFO | Exercise of warrants under the Eurofins warrants program. Number of warrants exercised: 750 is linked to the Eurofins warrants program Price(s) Volume(s) | Shares | 529.65 EUR | EUR | 750.0 | — |
| 2026-08-27 | 2026-09-01 | VIGNEAU François | Senior Vice President | Sale of shares is linked to the Eurofins stock option / free share / stock option program Price(s) Volume(s) | Shares | 72.6 EUR | EUR | 500.0 | — |
| 2026-08-24 | 2026-08-27 | VIGNEAU François | Senior Vice President | Exercise of stock options under the Eurofins stock option 1,400 program. Number of options exercised: is linked to the Eurofins stock option / free share / stock option program Price(s) Volume(s) | Shares | 32.5 EUR | EUR | 1400.0 | — |
| 2026-07-31 | 2026-07-31 | — | — | — | — | — | EUR | — | — |
| 2026-06-15 | 2026-06-17 | VIGNEAU François | Senior Vice President | Exercise of stock options under the Eurofins stock option programme. Number of options exercised: 1400 is linked to the Eurofins stock option / free share / stock option program Price(s) Volume(s) | Shares | 32.5 EUR | EUR | 1400.0 | — |
| 2026-06-15 | 2026-06-16 | VIGNEAU François | Senior Vice President | Exercise of stock options under the Eurofins stock option programme. Number of options exercised: 700 is linked to the Eurofins stock option / free share / stock option program Price(s) Volume(s) | Shares | 32.5 EUR | EUR | 1400.0 | — |
| 2026-06-15 | 2026-06-15 | — | — | — | — | — | EUR | — | — |
| 2026-06-11 | 2026-06-17 | VIGNEAU François | Senior Vice President | Exercise of stock options under the Eurofins stock option programme. Number of options exercised: 100 is linked to the Eurofins stock option / free share / stock option program Price(s) Volume(s) | Shares | 32.5 EUR | EUR | 100.0 | — |
| 2026-06-11 | 2026-06-16 | VIGNEAU François | Senior Vice President | Exercise of stock options under the Eurofins stock option programme. Number of options exercised: 700 is linked to the Eurofins stock option / free share / stock option program Price(s) Volume(s) | Shares | 32.5 EUR | EUR | 100.0 | — |
| 2026-06-09 | 2026-06-09 | — | — | — | — | — | EUR | — | — |
| 2026-06-08 | 2026-06-08 | — | — | — | — | — | EUR | — | — |
| 2026-06-04 | 2026-06-08 | VIGNEAU François | Senior Vice President | Sale of shares is linked to the Eurofins stock option / free share / stock option program Price(s) Volume(s) | Shares | 62.4 EUR | EUR | 1000.0 | — |
| 2026-05-22 | 2026-05-22 | — | — | — | — | — | EUR | — | — |
| 2026-05-07 | 2026-06-08 | VIGNEAU François | Senior Vice President | Exercise of stock options under the Eurofins stock option programme. Number of options exercised: 700 is linked to the Eurofins stock option / free share / stock option program Price(s) Volume(s) | Shares | 33.69 EUR | EUR | 700.0 | — |
| 2026-04-07 | 2026-04-07 | — | — | — | — | — | EUR | — | — |
| 2026-04-02 | 2026-04-03 | VIGNEAU François | Senior Vice President | Exercise of stock options under the Eurofins stock option programme. Number of options exercised: 700 is linked to the Eurofins stock option / free share / stock option program Price(s) Volume(s) | Shares | 33.69 EUR | EUR | 700.0 | — |
| 2026-04-02 | 2026-04-03 | VIGNEAU François | Senior Vice President | Sale of shares is linked to the Eurofins stock option / free share / stock option program Price(s) Volume(s) | Shares | 66.529 EUR | EUR | 500.0 | — |
| 2026-03-31 | 2026-04-02 | Timothy Scott Oostdyck | Member of Group Operating Council | Sale of shares Price(s) Volume(s) | Shares | 62.4388 EUR | EUR | 3000.0 | — |
| 2026-03-23 | 2026-03-26 | VIGNEAU François | Senior Vice President | Exercise of stock options under the Eurofins stock option programme. Number of options exercised: 700 is linked to the Eurofins stock option / free share / stock option program Price(s) Volume(s) | Shares | 33.69 EUR | EUR | 700.0 | — |
Showing 32 of 32 matching raw-feed row(s) from the current 365-day research window. Prices and reported values remain in the filing currency and its major unit (for example, UK pence are parsed as GBP). The screen-level € aggregate is separately FX-normalised for research ranking, not a trade-date conversion.
Follow new disclosures
Subscribe to new Europe disclosures. These are market-wide RSS feeds, not company-specific alerts.
Model & Sources
Signal history
47.8 / 100
Latest recorded score
↓ -3.2 ptssince the first recorded snapshot on 2026-10-28; 8 calendar days observed
- Recorded snapshots
- 5
- First snapshot
- 2026-10-28
There is not yet a 30-calendar-day comparison; earlier scores are not reconstructed. These are raw signal scores saved when each full scoring run completed. They describe changes in research ranking, not price performance or returns.
Why did it change?
Less than 30 days of comparable history is available, so factor movement is not yet decomposed.
Signal score history
Fixed 0–100 scale; dates are spaced by calendar time.
Recent recorded points
- 51.0
- 50.6
- 48.9
- 48.0
- 47.8
View all recorded scores
| Snapshot date | Signal score |
|---|---|
| 2026-10-28 | 51.0 |
| 2026-10-29 | 50.6 |
| 2026-11-03 | 48.9 |
| 2026-11-04 | 48.0 |
| 2026-11-05 | 47.8 |
Why this score? · Model details
Priority = 100 × Σ(fixed weight × 0–1 rule-based input)
| Factor | Weight | This company input | Point contribution |
|---|---|---|---|
| 15-day buyer breadth (count) | 35% | 0.300 | 10.5 |
| Qualified-buy size | 25% | 0.994 | 24.9 |
| Role informativeness (inverted) | 20% | 0.000 | 0.0 |
| Recency | 10% | 0.354 | 3.5 |
| Buy/sell conviction | 10% | 0.892 | 8.9 |
This is a heuristic ordering under the current rules, not a calibrated return forecast. It explains why candidates rank differently; the public-filing evidence and data limits are shown below.
Snapshot & identity
- Snapshot date
- 2026-11-05
- Ticker
- ERF.PA
- ISIN
- FR0014000MR3
- Sector
- Healthcare
- Industry
- Diagnostics & Research
Company logos by Parqet